Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 13;137(19):2585–2597. doi: 10.1182/blood.2020009471

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

PMC Copyright notice

Figure 5. — Complete remission from active AML after mLST infusion. MRI images of AML invading bone before (A) and after (B) mLST infusion. (C) Relapsed AML cells (CD33⁺ blasts; IHC). Hematoxylin and eosin; original magnification ×400. Cells were surrounded by a dense infiltrate of CD3⁺ T cells. IHC; original magnification ×10. Changes in frequency of circulating mLSTs after infusion, as measured by IFN-γ ELISpot (D) and polyclonality of circulating WT1-specific T cells, as estimated by ICS (E) performed on fresh PBMCs at the 6-month time point. (F) Change in the frequency of mLST-derived TCR clones represented as fold change from baseline in the repertoire frequency.